Selma Atalay (S Atalay)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 5

Top Topics

Rheumatoid Arthritis Patients

Disease Activity

Top Venues

The Journal of dermatological treatment

BMC dermatology

Drugs - real world outcomes

The British journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Lara S van der Schoot, Selma Atalay, Marisol E Otero, Wietske Kievit, Juul M P A van den Reek, Elke M G J de Jong
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab. The British journal of dermatology 187 (6) (2022)
Selma Atalay, Sophie E Berends, Hans M M Groenewoud, Ron A A Mathot, Marcellus D Njoo, Johannes M Mommers, Paul M Ossenkoppele, Marjolein I A Koetsier, Maartje A M Berends, Annick de Vries, Peter Cornelis Maria van de Kerkhof, Alfons A den Broeder, Elke M G J de Jong, Juul M P A van den Reek
Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial. The Journal of dermatological treatment 33 (5) (2022)
Marloes E van Muijen, Selma Atalay, L J van Vugt, L M D Vandermaesen, Juul M P A van den Reek, Elke M G J de Jong
Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab. Drugs - real world outcomes 8 (2) (2021)
Selma Atalay, Juul M P A van den Reek, Hans M M Groenewoud, Peter Cornelis Maria van de Kerkhof, Wietske Kievit, Elke M G J de Jong
Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice. The Journal of dermatological treatment (2021)
Selma Atalay, Juul M P A van den Reek, Lieke J van Vugt, Marisol E Otero, Peter C M van de Kerkhof, Alfons A den Broeder, Wietske Kievit, Elke M G J de Jong
Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial. BMC dermatology 17 (1) (2017)